

# MicroRNA-296 inhibits colorectal cancer cell growth and enhances apoptosis by targeting ARRB1-mediated AKT activation

ZHE ZHANG\*, XIAOHUA ZHONG\*, YIPIN XIAO and CHAO CHEN

Department of Gastrointestinal Surgery, Huizhou Municipal Central Hospital, Huizhou, Guangdong 516001, P.R. China

Received May 14, 2018; Accepted October 9, 2018

DOI: 10.3892/or.2018.6806

**Abstract.** Colorectal cancer (CRC) is the most commonly diagnosed tumor worldwide. However, the molecular mechanisms and biological processes of CRC remain unknown. The present study used reverse transcription-quantitative polymerase chain reaction to determine the expression levels of microRNA (miR)-296 in CRC cell lines and tissues. In addition, a miR-296 mimic was transfected into CRC cells, and the effects of miR-296 on cell proliferation and apoptosis were explored by MTT assay and flow cytometry. Luciferase assays were also performed to validate arrestin  $\beta 1$  (ARRB1) as a miR-296 target in SW480 and HCT-116 cells. The results demonstrated that miR-296 is a critical tumor suppressor which was downregulated in CRC patients. Increased expression levels of miR-296 were positively associated with a longer survival time of CRC patients. In addition, it was demonstrated that ARRB1 is a direct downstream target of miR-296. Upregulation of miR-296 in SW480 and HCT-116 cells resulted in suppressed cell growth and increased cell apoptosis through an ARRB1-dependent mechanism. Furthermore, the molecular mechanisms underlying the antitumor effect of miR-296 in CRC are at least in part due to the inactivation of the RAC- $\alpha$  serine/threonine-protein kinase (AKT) signaling pathway induced by the suppression of ARRB1 expression. Overall, the present study, to the best of the author's knowledge, is the first to demonstrate that the miR-296-ARRB1-AKT signaling pathway forms a critical feedback loop and mediates CRC carcinogenesis, and these findings may introduce a potential therapeutic strategy for the treatment of CRC.

## Introduction

Colorectal cancer (CRC) represents the most commonly diagnosed tumor worldwide, and the mortality rate of CRC is

higher in developed areas than in developing areas (1). Despite the current treatment strategies including surgery and radio-chemotherapy resulting in an improved treatment outcome, the median survival time of patients with malignant CRC is only 20-24 months (2). Currently, mounting evidence indicates that CRC is an epidemiologically heterogeneous disease and the molecular mechanisms of CRC are not fully clarified (3). Therefore, identification of novel molecular biomarkers involved in mediating the pathogenesis of CRC and predicting the prognosis of CRC patients is of primary concern.

MicroRNAs (miRNA), a class of single-stranded noncoding RNAs, play a critical role in degrading target mRNAs through forming hybrids with the 3'-untranslated region sequences. Several studies have revealed that miRNAs serve as oncogenes or tumor suppressors in CRC carcinogenesis (4). miR-296, mapped to the human 20q13.32 gene locus, is characterized as a critical mediator which is involved in the biological processes of cell growth, angiogenesis and apoptosis (5,6). Previously, miR-296 has been revealed to contribute to the development of various malignant tumors, such as ovarian, prostate, lung and breast cancers (7-10). It is noteworthy that Kunte *et al* (11) demonstrated that miR-296 is profoundly downregulated at the early stages of colon tumors and this may play a critical role in the pathological process of CRC neoplasia (11). However, its expression pattern, clinical significance, and biological functions in CRC remain unclear.

Arrestin  $\beta 1$  (ARRB1), a mainstay of the  $\beta$ -arrestin family, has been revealed to serve as a multifunctional adaptor contributing to the mediation of several signaling pathways which are involved in cancer cellular progression (12-14). Emerging evidence demonstrates that ARRB1 may interact with histone acetyl-transferase, facilitating its recruitment to target histones, with consequent increased chromatin acetylation and transcription activation (13,15,16). Although ARRB1 functions as a tumor oncogene that is associated with aggressive progression in various malignant cancers (17,18), its biological significance in CRC has not been extensively elucidated.

The present study verified that miR-296 was significantly decreased in CRC patients. Upregulation of miR-296 in CRC cells resulted in decreased cell proliferation and increased cell apoptosis. Importantly, ARRB1 was confirmed as a novel target of miR-296, and it was elucidated that the miR-296-ARRB1-RAC- $\alpha$  serine/threonine-protein kinase (AKT) axis contributes to regulation of tumor growth and cell apoptosis of SW480 and HCT-116 cells.

---

*Correspondence to:* Dr Chao Chen, Department of Gastrointestinal Surgery, Huizhou Municipal Central Hospital, 41 North Eling Road, Huizhou, Guangdong 516001, P.R. China  
E-mail: chenchao@126.com

\*Contributed equally

**Key words:** microRNA-296, colorectal cancer, apoptosis, arrestin  $\beta 1$

## Materials and methods

**Tissue samples.** CRC specimens were collected from 108 patients (60 male patients and 48 female patients; mean age, 53.32±11.32 years; median age, 55 years) with CRC at Huizhou Municipal Central Hospital (Huizhou, China) from January 2008 to December 2014. CRC tissue use in the present study was approved by the Specialty Committee on Ethics of Biomedicine Research (PJ2008-012-03), Huizhou Municipal Central Hospital. In this study, human tissue acquisition and use complied with the National Regulations on the Use of Clinical Samples in China, and was performed in accordance with the ethical standards from the Declaration of Helsinki. All patients gave written informed consent. In the present study, subjects' rights and interests were fully protected. There was no potential risk to the subjects. The board of ethics committee agreed to the study work as planned. The follow-up was carried out in all patients, with survival time being censored in July 2014. The follow-up procedure occurred every 6 months by telephone and the final follow-up for patients occurred in January 2014. The selection criteria were as follows: i) The subject was diagnosed with CRC and had no history of other tumors; ii) complete clinical data was available for the subject, including age, sex, clinical manifestations and mean tumor diameter; iii) patients receiving chemotherapy or radiotherapy prior to surgery were excluded. The clinical characteristics of patients with CRC are presented in Table I.

**Cell culture.** Human CRC cell lines (HT-29, SW620, LoVo, SW480 and HCT-116) and the normal colon cell line NCM 460 were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>.

**miRNAs and transfection.** The miR-296 mimic, the miR-NC and the miR-296 inhibitor were purchased from Invitrogen (Thermo Fisher Scientific, Inc.). Sequences were as follows: miR-296 mimics, sense 5'-AGGGCCCCCCCUCUAUCCUGU-3', antisense 5'-ACAGGAUUGAGGGGGGGCCCU-3'; miR-NC, sense 5'-UUCUCCGAGGACGUCUGACUGUTT-3', antisense 5'-ACGUGACACGUUCGGAGGGTT-3'; miR-296 inhibitor, 5'-ACAGGCCGGACAAGUCGAAUG. The ARRBI coding sequence was cloned into a pCDNA3.1 vector (Invitrogen; Thermo Fisher Scientific, Inc.), whereas a blank vector was used as a negative control. Short interfering RNA (siRNA) against ARRBI (ARRBI siRNA) (sense, 5'-CCGACUCACAGUCCAUAATT-3'; antisense, 5'-UUGAGGAUCUACGTACGGTT-3') and negative control with siRNA-negative control [green fluorescent protein (GFP)-siRNA] (sense, 5'-ACGCCAUUGGUAUCGUUTT-3'; antisense, 5'-AAGACUAUTUCAUUGGUCCTT-3') were synthesized and purified by Shanghai GenePharma Co., Ltd. (Shanghai, China). Cells were transfected with the miRNA mimics, siRNA and pCDNA3.1-ARRBI using Lipofectamine® 3000 Reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. For transfection, 2 µg miR-296

Table I. Association between miR-296 expression and clinico-pathological variables of colorectal cancer patients.

Characteristics	Value	MicroRNA-296 expression		P-value
		High	Low	
No. of patients	108	50	58	
Age, years				0.15
<50	64	30	34	
≥50	44	20	24	
Sex				0.14
Male	60	28	32	
Female	48	22	26	
MTD, cm				0.18
<5 cm	77	35	42	
≥5 cm	31	15	16	
Tumor location				0.11
Rectum	46	20	26	
Colon	62	30	32	
Distant metastasis				<b>0.02</b>
Present	41	24	17	
Absent	67	26	41	
Lymph node metastasis				<b>&lt;0.01</b>
Present	31	6	25	
Absent	77	54	23	
TNM stage				<b>&lt;0.01</b>
II	43	31	12	
III/IV	65	19	46	

MTD, mean tumor diameter; TNM, T category describes the primary tumor site; N category describes the regional lymph node involvement; M category describes the presence or otherwise of distant metastatic spread. Bold indicates significant differences.

mimic, miR-NC, miR-296 inhibitor, pcDNA3.1, pcDNA3.1-ARRBI, ARRBI siRNA or GFP-siRNA vectors were diluted in 200 µl Opti-MEM (Thermo Fisher Scientific, Inc.) and were incubated at room temperature for 5 min. Subsequently, the diluted vectors and Lipofectamine 3000 were combined and incubated for a further 20 min at room temperature, prior to their addition to cells (4×10<sup>5</sup>/well) seeded in 6-well plates. After transfection for 6 h, the culture medium was replaced with RPMI-1640 medium containing 10% FBS (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), followed by incubation for a further 24 h at 37°C and 5% CO<sub>2</sub>. At 48 h post-transfection, the cells were used in subsequent experiments. ARRBI was predicted as a direct downstream target of miR-296 by Target Scan 7.2 database (<http://www.targetscan.org>).

**Cell proliferation assay.** 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to assess cell viability. Cells were seeded in 96-well plates and were incubated with 0.2 mg/ml MTT for 4 h at 37°C. After removal of the medium, the formazan crystals produced by

live cells were dissolved in 150  $\mu$ l dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA) and the absorbance of each sample was read at a wavelength of 570 nm using an Ultra multi-functional microplate reader (Tecan US, Inc., Morrisville, NC, USA).

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.** Tumor specimens were frozen at  $-75^{\circ}\text{C}$  to use. Total RNA, including miRNA, was extracted from cells/tissues with TRIzol<sup>®</sup> reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and RNA was reverse transcribed into cDNA using a qPCR RT kit (FSQ-101; Toyobo Life Science, Osaka, Japan), according to the manufacturer's protocol. cDNA was amplified by Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen; Thermo Fisher Scientific, Inc.). RT-qPCR was performed according to the manufacturer's protocol. The PCR conditions were 10 min at  $95^{\circ}\text{C}$ , 1 min at  $55^{\circ}\text{C}$ , 40 cycles of 15 sec at  $95^{\circ}\text{C}$ , followed by 30 sec at  $55^{\circ}\text{C}$ . For mRNA analysis, RT-qPCR was performed using the Platinum SYBR Green qPCR SuperMix-UDG (Qiagen GmbH, Hilden, Germany) using the 7500 Fast Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The relative fold expression of the target gene was normalized to  $\beta$ -actin and was calculated according to the  $2^{-\Delta\Delta C_q}$  method (19). The PCR primer sequences for ARRB1 (forward, 5'-CCTGGATGTCTTGGGTCTG-3' and reverse, 5'-TGATGGGTTC TCCGTGGTA-3') were as previously described (20). The primer sequences for  $\beta$ -actin were as follows: Forward, 5'-ACCAACTGGGACGACATGGAGAAA-3' and reverse, 5'-TAGCACAGCCTGGATAGCAACGTA-3'.

**Northern blot analysis.** Northern blot analysis was performed as described previously (21). Antisense RNA probes were 3'-end-labeled with  $32\text{P}$ - $\gamma$ ATP by T4 polynucleotide kinase; miR-296 antisense probe sequence 5'-CCC UUCCAGAGGGCCCCCCCCUCAAU CCUGUUGUGCCUA-3' and U6 spliceosomal RNA antisense probe sequence 5'-GCAGGGGCCATGCTAATCT TCTCTGTATCG-3' were used.

**Luciferase reporter assay.** Cells were seeded in 24-well plates and incubated for 24 h prior to transfection. The ARRB1-3'untranslated region (UTR)-WT (wild-type) or ARRB1-3'UTR-MT (mutant) were transfected with a miR-296 mimic or miR-NC into cells. For the luciferase reporter assay,  $3 \times 10^4$  cells were seeded into 48-well plates overnight, followed by transfection with miR-296 (50 pmol/ml), *Renilla* luciferase pRL-TK vector (100 ng/ml; Promega Corporation, Madison, WI, USA) and pGL3 plasmid with WT/MT 3'UTR of ARRB1 gene using Lipofectamine<sup>®</sup> 2000. After transfection for 24 h, the luciferase activity was determined by the Dual Luciferase Reporter Assay System (Promega Corporation). *Renilla* luciferase activities were normalized to firefly luciferase activities.

**Apoptosis assay.** Cell apoptosis was assessed with ApoScreen Annexin V Apoptosis kit (Bender MedSystems, GmbH, Vienna, Austria). After being washed twice with PBS, cell samples were collected and fluorescein isothiocyanate added. All cells were analyzed by flow cytometry (FACScan; BD Biosciences, Franklin Lakes, NJ, USA). Analyses were performed using

CellQuest software version 5.0 (BD Biosciences). Experiments were conducted triple times.

**Protein extraction and western blotting.** Western blot analysis was conducted according to protocols described in a previous study (22). The protein concentration of cell lysates was quantified using a bicinchoninic acid kit (Beyotime Institute of Biotechnology, Haimen, China), and 50  $\mu$ g protein for each sample was separated by SDS-PAGE on 10% gels and was then transferred to a polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Billerica, MA, USA). The membranes were blocked in 5% non-fat milk diluted with Tris-buffered saline-Tween (TBST) (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.1% Tween-20) at room temperature for 1 h and were incubated overnight at  $4^{\circ}\text{C}$  with primary antibodies. Primary antibodies used were against ARRB1 (catalog no. sc-377015; 1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), AKT (catalog no. GTX110613; 1:600; GeneTex, Inc., Irvine, CA, USA), B cell lymphoma (Bcl)-2 (catalog no. sc-20067; 1:500; Santa Cruz Biotechnology, Inc.), signal transducer and activator of transcription 3 (STAT3) (catalog no. ab-11935; 1:500; Abcam, Cambridge, MA, USA), Bcl-2-associated X protein (Bax) (catalog no. sc-23959; 1:500; Santa Cruz Biotechnology, Inc.), Bcl-2 homologous antagonist/killer (Bak) (catalog no. sc-7873; 1:500; Santa Cruz Biotechnology, Inc.), NADPH oxidase activator (Noxa) (catalog no. 14766; 1:1,000; Cell Signaling Technology Inc., Danvers, MA, USA), p53 upregulated modulator of apoptosis (PUMA) (catalog no. 24633; 1:1,000; Cell Signaling Technology, Inc.) and  $\beta$ -actin (catalog no. ab8227; 1:1,000; Abcam). The membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit (catalog no. ab6721; 1:1,000; Abcam) or rabbit anti-mouse immunoglobulin G secondary antibodies (catalog no. ab6728; 1:1,000; Abcam) for 2 h at room temperature. The proteins were visualized using Enhanced Chemiluminescence Plus reagents (Amersham; GE Healthcare, Chicago, IL, USA), and band density was measured using ImageJ software (National Institutes of Health, Bethesda, MD, USA), and the values were normalized to the densitometric values of  $\beta$ -actin in each sample.

**Transmission electron microscopy (TEM).** Cultured cells were fixed for 2 h at  $4^{\circ}\text{C}$  with 2.5% glutaraldehyde in 0.2 M cacodylate buffer (pH 7.3), and post-fixed in 1% osmium tetroxide in 0.45 M cacodylate buffer (pH 7.3). The fixed material was dehydrated in a graded series of alcohol and embedded in Epon 812. For light microscopy, semi-thin sections were stained with Toluidine Blue and observed under a Reichert microscope equipped with Nomarski optics. Images were captured using a 12-bit charge-coupled device camera. For TEM, ultra-thin sections were classically contrasted with Ultracut S and were stained with uranyl acetate and lead citrate for 30 and 5 min at room temperature, respectively. The stained sections were observed under a JEOL transmission electron microscope (JEOL, Ltd., Tokyo, Japan) at x1200 magnification.

**Immunohistochemistry.** Human tissues were fixed in 4% formalin for 4 h at room temperature, and were then embedded in paraffin and cut into 3- $\mu$ m sections. The sections were then deparaffinized in xylol for 20 min at  $60^{\circ}\text{C}$  and rehydrated in a

graded ethanol series (75% alcohol for 1.5 h, 95% alcohol for 1.5 h, 95% alcohol for 1 h, anhydrous ethanol for 2.5 h). Antigen retrieval was performed by heating the samples in a microwave for 20 min in 1 mM EDTA buffer (pH 8.0). Thereafter, endogenous peroxidase activity was quenched by 30 min incubation in 3% methanolic hydrogen peroxide solution at room temperature. The sections were incubated in nonimmune serum (Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min and were then incubated overnight at 4°C in ARRB1 primary monoclonal antibody (cat. no., ab31868; 1:500; Abcam). After washing in TBST, the immunolabeled sections were incubated with a horseradish peroxidase-conjugated secondary antibody (catalog no. AS09 602; 1:500; Agrisera AB, Vännäs, Sweden) for 20 min at room temperature, and then with peroxidase-conjugated complex (Dako, Glostrup, Denmark) for 20 min. Finally, the sections were visualized with 3,3'-diaminobenzidine and counterstained with hematoxylin. To ensure the specificity of the immunostaining, negative controls were prepared by replacing the primary antibody with non-immune serum. Two independent pathologists examined five random fields (1 field = 0.159 mm<sup>2</sup> at x100 magnification; Leica DMRX; Leica Microsystems, Inc., Buffalo Grove, IL, USA) in each sample and scored each sample without knowledge of patient outcome (double-blinded).

**Statistical analysis.** All statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Experimental data are presented as the mean ± standard deviation from triplicate experiments. A Student's t-test was used to analyze differences between two groups. A one-way analysis of variance and Tukey's post hoc test was performed to detect statistical differences among multiple groups. Pearson's  $\chi^2$  tests were used for analysis of the association between clinicopathological features and miR-296 expression in CRC patients. The correlation between miR-296 and ARRB1 expression was examined by Spearman's correlation coefficient. Overall survival (OS) curves were calculated using the Kaplan-Meier method and were compared using the log-rank test. Possible prognostic factors were analyzed by univariate analysis for their potential association with OS. Factors with a  $P < 0.05$  in the univariate analysis were included in the multivariate analysis, in order to analyze their potential association with OS using Cox regression with the backward stepwise method.  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**miR-296 is frequently downregulated in CRC specimens.** The present study first used RT-qPCR to measure the miR-296 expression in 28 CRC tissues and corresponding adjacent normal specimens. It was demonstrated that miR-296 downregulation was detected in 25/28 (89.28%) CRC tumors (Fig. 1A), which indicated that the decrease of miR-296 is a frequent event in CRC. The RT-qPCR data revealed that miR-296 expression in the tumors was approximately 2.8-fold lower compared with adjacent normal tissues ( $4.98 \pm 1.02$  vs.  $1.99 \pm 0.54$ ;  $P < 0.05$ ; Fig. 1B). The mean miR-296 expression level of CRC tissues was 4.98, which was utilized to divide CRC patients into either a low expression group ( $< 4.98$ ,  $n = 58$ )

Table II. Univariate analysis of factors associated with survival of colorectal cancer patients.

Variable	Survival		
	HR	95% CI	P-value
Sex (male vs. female)	0.758	0.397-1.076	0.417
Age ( $\geq 50$ vs. $< 50$ )	0.812	0.276-1.374	0.398
MTD ( $\geq 5$ cm vs. $< 5$ cm)	0.541	0.322-1.179	0.743
MicroRNA-296 (low vs. high)	1.843	1.031-2.458	0.012 <sup>a</sup>
Tumor location	0.742	0.512-1.592	0.732
TNM stage	0.965	0.651-1.868	0.032 <sup>a</sup>
Lymph node metastasis	0.713	0.251-0.964	0.021 <sup>a</sup>
Distant metastasis	0.433	0.113-0.879	0.006 <sup>a</sup>

Univariate analysis, Cox proportional hazards regression model.

<sup>a</sup> $P < 0.05$  was considered to indicate a statistically significant difference. MTD, mean tumor diameter; TNM, T category describes the primary tumor site; N category describes the regional lymph node involvement; M category describes the presence or otherwise of distant metastatic spread; HR, hazard ratio; CI, confidence interval.

or a high expression group ( $\geq 4.98$ ,  $n = 50$ ). The present study then investigated the association between miR-296 expression and clinicopathological parameters (Table I). The expression level of miR-296 was inversely associated with tumor node metastasis (TNM) stage ( $P < 0.01$ ), lymph node metastasis ( $P < 0.01$ ) and distant metastasis ( $P = 0.02$ ). No significant association was identified between miR-296 expression and other clinical parameters.

Univariate survival analysis revealed a significant association between expression of miR-296, TNM stage ( $P = 0.032$ ), distant metastasis ( $P = 0.006$ ), lymph node metastasis ( $P = 0.021$ ) and recurrence-free survival rate (Table II), while no significant association was observed between recurrence-free survival rate and sex, age, tumor size, or tumor location. Multivariate analysis using the Cox proportional hazards model for all variables included in the univariate analysis further revealed that expression of miR-296 ( $P = 0.008$ ), TNM stage ( $P = 0.021$ ), distant metastasis ( $P = 0.007$ ), and lymph node metastasis ( $P = 0.002$ ) at diagnosis were independent prognostic factors for patients with CRC (Table III).

Next, the present study investigated the prognostic value of miR-296 between high and low expression groups using the Kaplan-Meier survival method. These results demonstrated that the patients with high expression levels of miR-296 exhibited a significantly prolonged overall survival (OS) compared with those with low expression levels of miR-296 ( $P < 0.05$ ; Fig. 1C).

The present study further measured the miR-296 expression in one normal colon cell line NCM 460 and five CRC cell lines, including HT-29, SW620, LoVo, SW480 and HCT-116 by RT-qPCR analysis (Fig. 1D) and Northern blotting (Fig. 1E). SW480 and HCT-116 cells revealed a significantly lower expression level of miR-296 compared with HT-29, SW620, LoVo and NCM 460 cells. Therefore, SW480 and HCT-116 cells were selected for use in subsequent experiments.




Figure 1. Expression levels of miR-296 in CRC tissues and cell lines. (A) miR-296 expression in 28 CRC tissues and corresponding adjacent normal tissues as determined by RT-qPCR analysis. (B) miR-296 expression was measured by RT-qPCR in adjacent normal tissues and CRC tissues. All expression levels were normalized to the level of U6 snRNA expression. \* $P < 0.05$ . (C) Kaplan-Meier survival curves according to miR-296 expression ( $P < 0.001$ ). (D) RT-qPCR analysis indicated that the expression level of miR-296 was significantly lower in SW480 and HCT-116 cells compared to the normal colon cell line NCM 460. \* $P < 0.05$  vs. the normal colon cell line NCM 460. (E) NB analysis revealed similar results; NB analyses were performed in triplicates, and representative results are shown. miR, microRNA; CRC, colorectal cancer; NB, Northern blot; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; sn, small nuclear.

*Overexpression of miR-296 inhibits cell survival and promotes cell apoptosis of CRC cells in vitro.* To investigate the antitumor effects of miR-296 in CRC cells, the present study upregulated the miR-296 expression level by treating with miR-296 mimics. As presented in Fig. 2A, transfection of SW480 and HCT-116 cells with miR-296 mimics resulted in a significant increase in miR-296 expression. Consistent with the previously demonstrated critical role of miR-296 in cell survival, miR-296 mimics-transfected SW480 and HCT-116 cells (overexpressing miR-296) revealed significantly lower survival rates compared with miR-NC transfected cells as evidenced by MTT assay (Fig. 2B). In addition, upregulation of miR-296 expression in SW480 and HCT-116 cell lines enhanced CRC cell apoptosis as measured by flow cytometry assays (Fig. 2C). Furthermore, TEM analysis revealed classical apoptotic changes in SW480 and HCT-116 cells transfected with miR-296 mimics, such as nuclear condensation and fragmentation and cell blebbing morphological alterations (Fig. 2D). These data strongly suggested that miR-296 suppressed CRC cell survival through enhancing cell apoptosis.

Table III. Multivariate analyses of factors associated with survival of colorectal patients.

Variable	HR	95% CI	P-value
MicroRNA-296 (low vs. high)	1.765	1.239-3.581	0.008 <sup>a</sup>
TNM stage	1.132	0.542-1.783	0.021 <sup>a</sup>
Lymph node metastasis	2.349	0.396-3.486	0.002 <sup>a</sup>
Distant metastasis	2.132	0.987-3.783	0.007 <sup>a</sup>

Multivariate analysis, Cox proportional hazards regression model; backward stepwise method. <sup>a</sup> $P < 0.05$  was considered to indicate a statistically significant difference. TNM, T category describes the primary tumor site; N category describes the regional lymph node involvement; M category describes the presence or otherwise of distant metastatic spread HR, hazard ratio; CI, confidence interval.

*miR-296-induced apoptosis is associated with dephosphorylation of AKT.* The AKT signaling pathway plays an important






Figure 2. Effects of miR-296 on cell proliferation, cell apoptosis and the expression of associated molecules in SW480 and HCT-116 cell lines. (A) Reverse transcription-quantitative polymerase chain reaction analysis demonstrated that miR-296 expression was significantly enhanced in SW480 and HCT-116 cells transfected with miR-296 mimics compared to cells transfected with miR-NC. \* $P < 0.05$  vs. miR-NC-transfected cells. (B) Effect of miR-296 upregulation on SW480 and HCT-116 cell proliferation as measured by MTT assay. \* $P < 0.05$  vs. miR-NC-transfected cells. (C) Effect of miR-296 upregulation on SW480 and HCT-116 cell apoptosis rates. The number of apoptotic cells was significantly higher in SW480 and HCT-116 cells overexpressing miR-296 as measured by propidium iodide staining and flow cytometry. \* $P < 0.05$ . (D) Morphological analysis of SW480 and HCT-116 cell apoptosis induced by miR-296 mimics. The morphology of colorectal cancer cells were imaged by TEM. Magnification in transmission electron microscopy analysis was  $\times 6,000$ . (E) Altered AKT signaling and apoptosis are associated with overexpression of miR-296. Detection of p-AKT, AKT, p-STAT3, STAT3 and apoptosis-associated proteins in SW480 and HCT-116 cells was performed by western blotting. miR, microRNA; NC, negative control; p, phosphorylated; AKT, RAC- $\alpha$  serine/threonine-protein kinase; STAT3, signal transducer and activator of transcription 3; mTOR, serine/threonine-protein kinase mTOR; Bcl-2, B cell lymphoma 2; Bak, Bcl-2 homologous antagonist/killer; Bax, Bcl-2 associated X, apoptosis regulator; Noxa, NADPH oxidase activator; Puma, p53 upregulated modulator of apoptosis.

role in controlling CRC cellular processes, such as apoptosis and proliferation. Signal transducer and activator of transcription 3 (STAT3) has been reported to mediate cell survival and apoptosis in CRC cells through the AKT signaling pathway. To determine whether AKT pathway activation is involved in miR-296-induced apoptosis, the expression and activities of AKT signaling pathway molecules were examined in cellular apoptosis pathways. Western blot analysis revealed that AKT phosphorylation and STAT3 phosphorylation were significantly lower in SW480 and HCT-116 cells expressing the miR-296 mimics compared with cells transfected with

miR-NC, while no changes in the expression levels of total AKT, total STAT3, p-serine/threonine-protein kinase mTOR (mTOR) and total mTOR were observed (Fig. 2E). Moreover, a significant decrease in the protein expression level of anti-apoptotic protein Bcl-2 in SW480 and HCT-116 cells overexpressing miR-296 was observed, whereas the protein levels of the apoptotic proteins Bax, Bak, Noxa and PUMA did not appear to differ between the two groups (Fig. 2E). These results suggested that AKT, STAT3 and Bcl-2 are critical downstream effectors of miR296-induced apoptosis and suppression of proliferation in SW480 and HCT-116 cells.




Figure 3. ARRBI is a novel target of miR-296. (A) The putative miR-296 binding sequences in ARRBI 3'-UTR. (B) A significant decrease in the relative luciferase activity was observed following co-transfection of ARRBI 3'-UTR with the miR-296 mimics \* $P < 0.05$  vs. miR-NC-transfected cells. (C) RT-qPCR analysis of miR-296 expression levels after the introduction of mimic control, miR-296 mimic, inhibitor control, or miR-296 inhibitor to SW480 cells. \* $P < 0.05$ . (D) RT-qPCR and (E) western blotting analysis of ARRBI protein levels following the introduction of mimic control, miR-296 mimic, inhibitor control, or miR-296 inhibitor to SW480 cells. \* $P < 0.05$ . (F) Representative immunostaining showed negative expression of ARRBI in miR-296 high-expressing CRC tissue and positive expression of ARRBI in miR-296 low-expressing CRC tissue. The expression of ARRBI protein in miR-296 high-expressing tumors was significantly lower than that in miR-296 low-expressing tumors. Scale bar, 10  $\mu$ m. \* $P < 0.05$ . (G) The expression of ARRBI mRNA in miR-296 high-expressing tumors was significantly lower than that in miR-296 low-expressing tumors. \* $P < 0.01$ . (H) A significant inverse correlation between the mRNA levels of miR-296 and ARRBI was observed in CRC tissues.  $P = 0.0055$ . miR, microRNA; NC, negative control; UTR, untranslated region; CRC, colorectal cancer; WT, wild-type; MT, mutated; ARRBI, arrestin  $\beta$ 1.

Upregulation of miR-296 expression in CRC cells may inhibit the activity of the AKT-STAT3 signaling pathway, which ultimately results in promoting CRC cell apoptosis by suppressing levels of Bcl-2, an important anti-apoptotic protein.

**ARRBI is a direct target of miR-296.** Since ARRBI was predicted as a direct downstream target of miR-296 using the TargetScan 7.2 database (<http://www.targetscan.org>) (Fig. 3A), the present study next validated whether miR-296 regulates ARRBI expression by using a luciferase reporter gene assay. As presented in Fig. 3B, overexpression of miR-296 in SW480 cells significantly suppressed the luciferase activity of the WT 3'-UTR of ARRBI, whereas no change in the luciferase activity of the Mut 3'-UTR of ARRBI was observed. RT-qPCR revealed that miR-296 mimics resulted in a significant increase in miR-296 expression and miR-296 inhibitor caused a significant decrease in miR-296 expression in SW480 cells (Fig. 3C). In addition, upregulation of miR-296 expression substantially decreased endogenous ARRBI mRNA and protein levels in SW480 cells expressing miR-296 mimics compared with cells expressing only miR-NC, detected using RT-qPCR and western blot analysis (Fig. 3D and E). In contrast to SW480 cells overexpressing miR-296, SW480 cells underexpressing miR-296 showed enhanced ARRBI mRNA and protein expression levels compared with the control (Fig. 3D and E). Furthermore,

the association between miR-296 level and ARRBI expression in CRC tissues was investigated, to confirm that ARRBI was a novel target of miR-296. Immunohistochemical (ICH) staining indicated that ARRBI expression in CRC with high expression level of miR-296 was significantly lower than in CRC with low miR-296 expression ( $P < 0.05$ ; Fig. 3F). RT-qPCR analysis revealed that ARRBI mRNA expression was lower in the miR-296 high-expressing tumors compared with miR-296 low-expressing tumors, consistent with results from ICH ( $P < 0.05$ ; Fig. 3G). As depicted in Fig. 3H, an inverse correlation was observed between ARRBI and miR-296 expression levels in human CRC tissues ( $r = -0.352$ ,  $P = 0.0055$ ). Therefore, the aforementioned results suggested that miR-296 reduced ARRBI expression by targeting its 3'-UTR and ARRBI is a direct downstream target of miR-296 in CRC.

**ARRBI functions as an oncogene in CRC.** The present study examined ARRBI mRNA and protein expression levels in HT-29, SW620, LoVo, SW480 and HCT-116 cell lines by RT-qPCR and western blot analysis (Fig. 4A and B). As predicted, SW480 and HCT-116 cells exhibited significantly increased ARRBI expression levels compared with HT-29, SW620, and LoVo cells, at both the mRNA and protein level. Therefore, SW480 and HCT-116 cells were selected for subsequent *in vitro* experiments. Western blot analysis revealed




Figure 4. Overexpression of ARRB1 partially rescues miR-296-regulated cell growth and apoptosis in SW480 and HCT-116 cells. (A) mRNA levels of ARRB1 measured in five CRC cell lines by RT-qPCR. \* $P < 0.05$  vs. HT-29, SW620 and LoVo cells. (B) Expression of ARRB1 protein in five CRC cell lines measured by western blotting. (C) The mRNA levels of ARRB1 expression were suppressed in SW480 and HCT-116 cells after transfection of ARRB1 siRNA for 72 h, detected by RT-qPCR. \* $P < 0.05$  vs. GFP-siRNA-transfected cells. (D) Western blot analysis showing the results of ARRB1 expression in HCT-116 and SW480 cells after ARRB1-siRNA transfection. (E) Effect of ARRB1 underexpression on SW480 and HCT-116 cell proliferation, as measured by MTT assay. \* $P < 0.05$  vs. GFP-siRNA-transfected cells. (F) Effect of ARRB1 underexpression on SW480 and HCT-116 cell apoptosis rates. The number of apoptotic cells was significantly higher in SW480 and HCT-116 cells underexpressing ARRB1, as measured by apoptosis assay. \* $P < 0.05$ . (G) Western blot analysis of CRC cells co-transfected with miR-296 mimics and Lenti-ARRB1. (H) MTT assay of SW480 and HCT-116 cells co-transfected with miR-296 mimics and Lenti-ARRB1 or the control. \* $P < 0.05$  vs. SW480 and HCT-116 cells co-transfected with miR-296 mimics and Lenti-ARRB1. (I) Apoptosis assay of SW480 and HCT-116 cells co-transfected with miR-296 mimics and Lenti-ARRB1 or the control. \* $P < 0.05$ , \*\* $P < 0.01$ . (J) ARRB1 overexpression blocks the effect of miR-296 on dephosphorylation of AKT signaling without affecting total AKT and STAT3 expression. Western blot analysis also indicated that miR-296 suppressed Bcl-2 protein expression, via regulation of ARRB1. Western blot analyses were performed in triplicate, and representative results are shown. miR, microRNA; NC, negative control; CRC, colorectal cancer; ARRB1, arrestin  $\beta$ 1; si, small interfering; GFP, green fluorescent protein; p, phosphorylated; AKT, RAC- $\alpha$  serine/threonine-protein kinase; STAT3, signal transducer and activator of transcription 3; Bcl-2, B cell lymphoma-2.

that both ARRB1 mRNA and protein expression levels were significantly inhibited by siRNA targeting ARRB1 (Fig. 4C and D). An MTT assay was next used to investigate the contribution of ARRB1 to SW480 and HCT-116 cell proliferation. It was observed that downregulation of ARRB1 led to a significant reduction in survival of SW480 and HCT-116 cells (Fig. 4E). In addition, flow cytometry analysis revealed that SW480 and HCT-116 cells that underexpressed ARRB1 exhibited a significantly increased rate of apoptosis relative to cells expressing the GFP-siRNA vector (Fig. 4F). These results

clearly indicated that ARRB1 functions as a critical oncogene through enhancing cell survival and suppressing cell apoptosis *in vitro*.

*miR-296 inhibits cell growth and promotes cell apoptosis through suppressing ARRB1-mediated AKT activation.* To figure out whether ARRB1 is a critical mediator in miR-296-regulated cell survival and apoptosis, full-length ARRB1 was transfected into SW480 and HCT-116 cells overexpressing miR-296. It was verified that miR-296 mimics significantly



decreased ARRB1 protein levels and this effect could be in part alleviated by ARRB1 transfection in CRC cells, detected by western blot analysis (Fig. 4G). The MTT and apoptosis assays revealed that upregulation of ARRB1 in SW480 and HCT-116 cells transfected with miR-296 mimics reversed the decreased growth and enhanced apoptosis that was observed in cells transfected only with miR-296 mimics (Fig. 4H and I). These results implied that miR-296 suppresses cell growth and induces cell apoptosis by an ARRB1-dependent mechanism.

The association between miR-296 and ARRB1 in SW480 and HCT-116 cells prompted investigation of the activation of the AKT signaling pathway under altering ARRB1 expression levels. Following enhancement of the expression of ARRB1 in SW480 and HCT-116 cells by using Lenti-ARRB1, it was observed that ARRB1 activated the AKT signaling pathway by increasing the phosphorylation levels of AKT and STAT3 without affecting the total AKT and STAT3 expression. The expression levels of Bcl-2 increased in CRC cells transfected with Lenti-ARRB1. Notably, overexpression of ARRB1 significantly abrogated the decrease in the phosphorylation of AKT and phosphorylation of STAT3 in cells overexpressing miR-296 (Fig. 4J). In addition, ARRB1 rescued cells from the inhibitory effect of miR-296 on Bcl-2 expression (Fig. 4J). These results demonstrated that miR-296-induced apoptosis in CRC may be associated with the inactivation of AKT/STAT3 signaling pathway, which is regulated by ARRB1.

## Discussion

Previous evidence has indicated that miR-296 serves as a tumor suppressor in a variety of malignant cancer cells. Previously, Shivapurkar *et al* (23) demonstrated that underexpression of miR-296 in serum predicts chemotherapy resistance in patients receiving systemic chemotherapy for metastatic colon cancer. Furthermore, it was reported that miR-296 inhibits CRC metastasis by mediating S100A4, which highlights the potential of miR-296 as an important target against CRC metastasis (24). These results prompted speculation that miR-296 may serve as a tumor suppressor for CRC cells. The present study revealed that miR-296 was underexpressed in 89.28% of the CRC patients. Kaplan-Meier analysis revealed that lower miR-296 expression was positively associated with poor prognosis. The results identified miR-296 as a promising predictive biomarker, which may aid in the optimization of treatment stratification. Notably, it was demonstrated that SW480 and HCT-116 cells revealed significantly lower expression levels of miR-296 compared with HT-29, SW620, and LoVo cells. It has been reported that miR-296 directly targets protein kinase C  $\alpha$  to suppress focal adhesion kinase-Ras-c-Myc signaling, thus stimulating its own expression in a feedback loop in lung adenocarcinoma (25). Deng *et al* (26) demonstrated that suppression of MK2 expression downregulates Ras/Braf/Erk/Mek/c-Myc axis and promotes cytoplasmic translocation of c-Myc, which activates miR-296 expression by a feedback loop (26). ATCC information suggests that both SW480 and HCT-116 cells have mutations in the Ras proto-oncogene, while the other three lines (HT-29, SW620, and LoVo cells) have no mutations in the Ras proto-oncogene. Perhaps these altered Ras mutations may contribute to the lower expression level of miR-296. However, this issue requires further studies in the future.

Over the past decades, a wide range of studies have demonstrated that the AKT signaling pathway is associated with multiple cellular functions. Accumulating evidence suggests that the AKT signaling pathway regulates various cellular biological processes including cell apoptosis, proliferation, angiogenesis, and invasion, all of which are involved in CRC development. It is noteworthy that miR-296 targets AKT2 in pancreatic cancer and functions as a potential tumor suppressor (27). Therefore, it is reasonable to speculate that miR-296 may mediate several important signaling pathways, particularly the AKT signaling pathway, and ultimately contributes to tumorigenesis. ARRB1 serves as a ubiquitous, multifunctional scaffolding protein, and it connects the activated receptors with diverse signaling pathways within the cell (12,17). ARRB1 may have different effects on cellular processes in different signaling pathways. The repressed protein ARRB1 indirectly regulates transcription factors involved in DNA damage processing and apoptosis through binding to regulators such as I $\kappa$ B $\alpha$  and MDM2 (28). Furthermore, it was reported that ARRB1 mediates prolonged phosphorylation of AKT in glioblastoma cells induced by NK1R activation (29). Given the importance of ARRB1 in the AKT signaling pathway, the present study examined the expression of ARRB1 after miR-296 transfection, to clarify the mechanisms of apoptosis in CRC cells. It was indicated that miR-296 enhanced CRC cell apoptosis by inhibiting ARRB1 expression, a novel downstream target of miR-296, which serves to reduce AKT signaling pathway activity, leading to increased apoptosis. However, the *in vivo* functions and molecular mechanism of miR-296 and ARRB1 in CRC remain to be fully elucidated, and further studies are required in the future.

Apoptosis is an inborn process that allows the cells to systematically inactivate, destroy their own components and ultimately results in cell death. Bcl-2 is a proto-oncogene that suppresses apoptosis and has been indicated in the pathogenesis of various tumor types including CRC (30). In addition, CRC with high Bcl-2 expression levels exhibits lower rates of spontaneous apoptosis compared with CRC with low Bcl-2 expression (31). Aberrant activation of the Bcl-2 gene may be an early event in colorectal carcinogenesis that can suppress apoptosis *in vivo* (31). Interestingly, miR-296 is also suppressed at the premalignant stages of colon carcinogenesis (11). The present study indicated that miR-296 regulates Bcl-2 expression in CRC cells, induced by AKT pathway inactivation. The lack of Bcl-2 activation in miR-296 transfected CRC cells was at least partly responsible for the enhanced cell apoptosis. Moreover, it was demonstrated that overexpression of miR-296 in CRC resulted in a decrease in Bcl-2 expression, whereas the level of Bax, or PUMA remained unchanged, implying a functional interaction between miR-296 and the Bcl-2-dependent apoptosis pathways. Although there is no direct interaction of miR-296 with Bcl-2, it is reasonable to speculate that miR-296 plays a critical role in the Bcl-2 pathway. Additional studies are essential to fully describe the miR-296-associated Bcl-2 pathway in the future.

In conclusion, the results of the present study indicated that ARRB1 is a direct target of miR-296. In addition, miR-296 resulted in the promotion of cell apoptosis and the suppression of cell growth by regulating the ARRB1-AKT-mediated signaling pathway. The results add to the accumulating evidence

that miR-296 plays a critical role in CRC tumorigenesis and targeting miR-296 may represent an ideal gene-targeting strategy for CRC treatment.

## Acknowledgements

Not applicable.

## Funding

No funding was received.

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Authors' contributions

ZZ and CC designed and performed the experiments; YX, ZZ, and XZ contributed to the data analysis; CC enrolled patients and measured the RNA levels in the clinical samples; ZZ initiated the study and wrote the manuscript; and all authors have read and approved the final version of the manuscript.

## Ethics approval and consent to participate

The use of human tissues was approved by the Specialty Committee on Ethics of Biomedicine Research (PJ2008-012-03), Huizhou Municipal Central Hospital, and patient consent was obtained.

## Patient consent for publication

Written informed consent was obtained.

## Competing interests

The authors declare that they have no competing interests.

## References

- Wang J, Song YX, Ma B, Wang JJ, Sun JX, Chen XW, Zhao JH, Yang YC and Wang ZN: Regulatory roles of non-coding RNAs in colorectal cancer. *Int J Mol Sci* 16: 19886-19919, 2015.
- Konda B, Shum H and Rajdev L: Anti-angiogenic agents in metastatic colorectal cancer. *World J Gastrointest Oncol* 7: 71-86, 2015.
- Kocarnik JM, Shiovitz S and Phipps AI: Molecular phenotypes of colorectal cancer and potential clinical applications. *Gastroenterol Rep (Oxf)* 3: 269-276, 2015.
- Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. *Adv Exp Med Biol* 774: 1-20, 2013.
- Wang L, Bo X, Zheng Q, Xiao X, Wu L and Li B: miR-296 inhibits proliferation and induces apoptosis by targeting FGFR1 in human hepatocellular carcinoma. *FEBS Lett* 590: 4252-4262, 2016.
- Dinami R, Buemi V, Sestito R, Zappone A, Ciani Y, Mano M, Petti E, Sacconi A, Blandino G, Giacca M, *et al*: Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. *Oncotarget* 8: 95674-95691, 2017.
- Lee KH, Lin FC, Hsu TI, Lin JT, Guo JH, Tsai CH, Lee YC, Lee YC, Chen CL, Hsiao M, *et al*: MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. *Biochim Biophys Acta* 1843: 2055-2066, 2014.
- Yan W, Chen J, Chen Z and Chen H: Deregulated miR-296/S100A4 axis promotes tumor invasion by inducing epithelial-mesenchymal transition in human ovarian cancer. *Am J Cancer Res* 6: 260-269, 2016.
- Luo W, Lin Y, Meng S, Guo Y, Zhang J and Zhang W: miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. *Am J Transl Res* 8: 1848-1856, 2016.
- Savi F, Forno I, Favarsani A, Luciani A, Caldiera S, Gatti S, Foa P, Ricca D, Bulfamante G, Vaira V, *et al*: miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo. *Clin Sci (Lond)* 127: 233-242, 2014.
- Kunte DP, Delacruz M, Wali RK, Menon A, Du H, Stypula Y, Patel A, Backman V and Roy HK: Dysregulation of microRNAs in colonic field carcinogenesis: Implications for screening. *PLoS One* 7: e45591, 2012.
- Witherow DS, Garrison TR, Miller WE and Lefkowitz RJ: beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. *Proc Natl Acad Sci USA* 101: 8603-8607, 2004.
- Miele E, Po A, Begalli F, Antonucci L, Mastronuzzi A, Marras CE, Carai A, Cucchi D, Abballe L, Besharat ZM, *et al*: beta-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. *BMC Cancer* 17: 488, 2017.
- Kraemer A, Barjaktarovic Z, Sarioglu H, Winkler K, Eckardt-Schupp F, Tapio S, Atkinson MJ and Moertl S: Cell survival following radiation exposure requires miR-525-3p mediated suppression of ARRB1 and TXN1. *PLoS One* 8: e77484, 2013.
- Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, Zhang M, Bao G, Wang F, Zhang X, *et al*: A nuclear function of beta-arrestin1 in GPCR signaling: Regulation of histone acetylation and gene transcription. *Cell* 123: 833-847, 2005.
- Parathath SR, Mainwaring LA, Fernandez-L A, Guldal CG, Nahlé Z and Kenney AM: beta-Arrestin-1 links mitogenic sonic hedgehog signaling to the cell cycle exit machinery in neural precursors. *Cell Cycle* 9: 4013-4024, 2010.
- Yang Y, Guo Y, Tan S, Ke B, Tao J, Liu H, Jiang J, Chen J, Chen G and Wu B: beta-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. *Nat Commun* 6: 7369, 2015.
- Zecchini V, Madhu B, Russell R, Pérttega-Gomes N, Warren A, Gaude E, Borlido J, Stark R, Ireland-Zecchini H, Rao R, *et al*: Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. *EMBO J* 33: 1365-1382, 2014.
- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-Delta Delta C(T)</sup> Method. *Methods* 25: 402-408, 2001.
- Ma H, Wang L, Zhang T, Shen H and Du J: Loss of beta-arrestin1 expression predicts unfavorable prognosis for non-small cell lung cancer patients. *Tumour Biol* 37: 1341-1347, 2016.
- Hong L, Han Y, Zhang H, Li M, Gong T, Sun L, Wu K, Zhao Q and Fan D: The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. *Ann Surg* 251: 1056-1063, 2010.
- Wang Q, Qian J, Wang J, Luo C, Chen J, Hu G and Lu Y: Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells. *J Neurooncol* 112: 73-82, 2013.
- Shivapurkar N, Mikhail S, Navarro R, Bai W, Marshall J, Hwang J, Pishvaian M, Wellstein A and He AR: Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. *Int J Colorectal Dis* 28: 887, 2013.
- He Z, Yu L, Luo S, Li M, Li J, Li Q, Sun Y and Wang C: miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4. *BMC Cancer* 17: 140, 2017.
- Fu Q, Song X, Liu Z, Deng X, Luo R, Ge C, Li R, Li Z, Zhao M, Chen Y, *et al*: miRomics and proteomics reveal a miR-296-3p/PRKCA/FAK/Ras/c-Myc feedback loop modulated by HDGF/DDX5/beta-catenin complex in lung adenocarcinoma. *Clin Cancer Res* 23: 6336-6350, 2017.
- Deng X, Liu Z, Liu X, Fu Q, Deng T, Lu J, Liu Y, Liang Z, Jiang Q, Cheng C *et al*: miR-296-3p negatively regulated by nicotine stimulates cytoplasmic translocation of c-Myc via MK2 to suppress chemotherapy resistance. *Mol Ther* 26: 1066-1081, 2018.

27. Li H, Li J, Shi B and Chen F: MicroRNA-296 targets AKT2 in pancreatic cancer and functions as a potential tumor suppressor. *Mol Med Rep* 16: 466-472, 2017.
28. Ma L and Pei G: Beta-arrestin signaling and regulation of transcription. *J Cell Sci* 120: 213-218, 2007.
29. Zhang YX, Li XF, Yuan GQ, Hu H, Song XY, Li JY, Miao XK, Zhou TX, Yang WL, Zhang XW, *et al*:  $\beta$ -Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition. *J Biol Chem* 292: 8933-8947, 2017.
30. Guzińska-Ustymowicz K, Pryczynicz A, Kemona A and Czyżewska J: Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. *Anticancer Res* 29: 3049-3052, 2009.
31. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. *Cancer Res* 55: 237-241, 1995.